Resumen de: EP3757572A1

The present invention concerns the rapid and selective detection of pathogenic bacteria expressing a lectin-type adhesin in a biological environment using a cellulose support functionalized with a ligand of a lectin-type adhesin, and its use for the diagnostic of infection with pathogenic bacteria expressing a lectin-type adhesin, for example in the context of Crohn's disease or in urinary tract infections.

Resumen de: WO2020260445A1

The present invention concerns the rapid and selective detection of pathogenic bacteria expressing a lectin-type adhesin in a biological environment using a cellulose support functionalized with a ligand of a lectin-type adhesin, and its use for the diagnostic of infection with pathogenic bacteria expressing a lectin- type adhesin, for example in the context of Crohn's disease or in urinary tract infections.

Resumen de: WO2020264239A1

The invention relates to methods for diagnosing or assessing the risk of developing chronic lung and bowel disease in pre-term infants by measuring the nitrate reductase activity in oral microbiome samples from the infant. The invention further relates to methods for guiding the care of pre-term infants based on measuring the nitrate reductase activity in oral microbiome samples from the infant.

Resumen de: US2020399673A1

This document relates to methods and materials involved in assessing and/or treating a mammal having a functional gastrointestinal disorder (FGID) such as irritable bowel syndrome (IBS). For example, methods and materials provided herein can be used for determining if a mammal having a FGID is likely to respond to a particular FGID treatment. This document also provides methods and materials for treating a mammal having a FGID.

Resumen de: US2020400666A1

The present invention provides a diagnostic method which may be used to determine the likelihood that a subject with Irritable Bowel Syndrome (IBS) will respond to treatment with an IBS intervention diet or faecal microbiota transplant (FMT). In particular, the method may be used to predict, or determine the likelihood of, a positive response of the subject with IBS to treatment with an IBS intervention diet or FMT, especially to determine the likelihood that the dietary intervention or FMT may have a positive (i.e. beneficial) effect on the subject's GI tract, specifically the GI tract microbiota, or other symptoms or complications of IBS (e.g. reducing severity thereof). The method of the present invention is based on analysing the abundance of certain bacteria in GI tract samples, e.g. by nucleic acid analysis.

Resumen de: US2020392231A1

This disclosure relates to methods of using a specific binding agent that targets alpha4 beta7 integrin to treat or prevent fatty liver diseases such as, hepatic steatosis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). In certain embodiments, a specific binding agent that targets alpha4 beta7 integrin is an antibody. In certain embodiments, antibody that binds alpha4 beta7 integrin is vedolizumab. In certain embodiments, the subject is or is not diagnosed with inflammatory bowel disease.

Resumen de: WO2020250068A1

A method is described of analyzing the microbiome, including the virome, of a patient. Viral marker clusters for diagnosing inflammatory bowel disease, Crohn's disease and ulcerative colitis are identified from such analysis. Methods of diagnosis and treatment of dysbiosis and various disorders, such as inflammatory bowel disease, Crohn's disease and ulcerative colitis, are also included.

Resumen de: WO2020242081A1

The present invention relates to a method for diagnosis of colitis through qPCR analysis and to a method for diagnosis of colitis by measuring levels of microorganisms in fecal samples to be analyzed. The diagnosis method according to the present invention can predict and/or diagnose colitis at high accuracy and sensitivity by using feces, which can be easily acquired without pain from a subject to be diagnosed, and as such, can find a wide range of applications in the colitis diagnosis field and, as a result, is expected to enable early diagnosis of colitis, thereby remarkably increasing the effects of colitis cancer treatment.

Resumen de: AU2019261933A1

Described herein are methods and systems for identifying subjects suitable for treatment with an inhibitor of CD30L activity or expression, such as an anti-CD30L antibody. Methods and systems disclosed herein identify subjects suitable for treatment based on a presence of a genotype that is indicative of a disease or condition in the subject for which an inhibitor of CD30L is a suitable treatment. Exemplary conditions include both Crohns disease and primary sclerosing cholangitis. Compositions used to detect the genotypes described herein, and methods of using them are also provided.

Resumen de: WO2020242081A1

The present invention relates to a method for diagnosis of colitis through qPCR analysis and to a method for diagnosis of colitis by measuring levels of microorganisms in fecal samples to be analyzed. The diagnosis method according to the present invention can predict and/or diagnose colitis at high accuracy and sensitivity by using feces, which can be easily acquired without pain from a subject to be diagnosed, and as such, can find a wide range of applications in the colitis diagnosis field and, as a result, is expected to enable early diagnosis of colitis, thereby remarkably increasing the effects of colitis cancer treatment.

Resumen de: US2020371120A1

Methods, kits and compositions for diagnosing and treating autoimmue diseases such as rheumatiodi arthritis, Crohn's disease, and ulcerative colitis.

Resumen de: WO2020226498A1

The invention relates generally to biomarkers, methods and kits to predict therapy response in patients, in particular in patients having inflammatory bowel disease (IBD). Provided is a method for predicting whether a human subject is likely to show a clinical response to therapy with an antibody or pharmacological antagonist that targets α4β7 integrin, preferably vedolizumab induction therapy, comprising (i) determining the level of eotaxin-1 in a sample obtained from the subject, and; (ii) classifying the subject as a responder based on the level of eotaxin-1.

Resumen de: US2020345045A1

Provided are food and drink ingredients produced from wheat grain which has a low level (2-30%) of total starch branching enzyme II activity and an amylose content in the starch of at least 50% (w/w), and processes for producing and using the ingredients. Also provided are foods produced from the ingredients which may be used in humans to improve one or more parameters of metabolic health, bowel health or cardiovascular health.

Resumen de: WO2020219549A1

The present disclosure provides methods and systems of identifying an inflammatory disease or condition, e.g., an inflammatory bowel disease in a subject using a DeepLearning model. The DeepLearning model may be used to predict, treat, monitor, and/or prevent the inflammatory disease or condition in the subject, as well as to characterize a subtype of the inflammatory disease or condition.

Resumen de: US2020342958A1

The present disclosure provides methods and systems of identifying an inflammatory disease or condition, e.g., an inflammatory bowel disease in a subject using a DeepLearning model. The DeepLearning model may be used to predict, treat, monitor, and/or prevent the inflammatory disease or condition in the subject, as well as to characterize a subtype of the inflammatory disease or condition.

Resumen de: WO2020213732A1

[Problem] To provide a testing method for irritable bowel syndrome. [Solution] A method for providing information on whether a sample obtained from an individual subject or a subject population (user) is associated with irritable bowel syndrome (IBS), wherein the method includes the following steps: (a) a step for generating a data set including a gut microbiota profile in the user, (b) a step for statistical processing of the data set, and (c) a step for providing the results of the processing as an indicator for evaluating whether the sample is a sample associated with IBS.

Resumen de: US2020330555A1

Provided herein are methods of treating or preventing gastrointestinal motility-related disorders, treating or preventing constipation or stimulating bowel function, comprising using variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics).

Resumen de: US2020325538A1

Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.

Resumen de: US2020318162A1

The present invention describes methods of identifying subjects susceptible to fibrosis by targeting bacteria found in intestine-related adipose tissue such as creeping fat, ileal mucosa or related tissue. Based on subject's susceptibility to developing fibrosis, different intervention or treatment options can be used.

Resumen de: WO2020201457A1

The application provides new and improved methods for diagnosing IBS.

Resumen de: WO2020205911A1

The present disclosure relates to methods for diagnosing and treating inflammatory bowel disease (IBD) in companion animals.

Resumen de: CN111733226A

The invention discloses a circular RNA marker for detecting Crohn's disease and an application. In 155 upregulated circRNA molecules of a CD patient subjected to chip screening, the has_circRNA _ 009084 has excellent performance in evaluation of diagnosis sensitivity and specificity. The hsa _ circRNA _ 009084 for CD diagnosis provided by the invention has no related literature reports and patentapplications at home and abroad. According to the technology, only an RT-PCR method is needed for detecting hsa _ circRNA _ 009084 molecules in blood, the operation is simple and easy, and the clinical application and popularization feasibility is high; and the hsa _ circRNA _ 009084 can be applied to rapid judgment of CD diagnosis and curative effect. The invention provides the circular RNA marker for detecting Crohn's disease. The circular RNA marker is hsa _ circRNA _ 009084. The invention provides the application of the circular RNA marker for detecting the Crohn's disease. The circular RNA marker is hsa _ circRNA _ 009084 which is used as a marker in a Crohn's disease detection method.

Resumen de: US2020309790A1

Disclosed are methods for conducting diagnostic tests for the detection of the inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. Also described are methods for monitoring a patient by administering tests of the present invention. Also described are methods for monitoring patient's treatment by administering tests of the present invention. Also described are methods for evaluating the effectiveness of a drug or a drug candidate by administering tests of the present invention to samples from patients, animal models, and cell cultures treated with a drug or a drug candidate. Also disclosed are methods for determining the usefulness of analytes, e.g. cytokines, for acting as diagnostic and monitoring markers for inflammatory bowel disease in the various methods of the invention.

Resumen de: US2020311910A1

Some embodiments are directed to a process for quantifying changes in the intestinal mucosa caused by a chronic inflammatory intestinal disease in individuals, an ex vivo process for diagnosing a chronic inflammatory intestinal disease in individuals, and an ex vivo process for the differential diagnosis of Crohn's disease versus ulcerative colitis in individuals.

Resumen de: US2020308644A1

Diagnostic methods for assessing risk of or presence of inflammatory bowel disease in a patient based on glycosyltransferase or histo-blood group antigen signatures or a combination thereof. Also disclosed herein are prognostic methods for monitoring inflammatory bowel disease progression in a patient.